HUALAN NPM(301093)

Search documents
股市必读:华兰股份(301093)5月23日主力资金净流出428.5万元
Sou Hu Cai Jing· 2025-05-25 20:51
Core Viewpoint - On May 23, 2025, Hualan Co., Ltd. (301093) closed at 27.55 yuan, down 1.01%, with a turnover rate of 0.91% and a trading volume of 11,500 shares, amounting to a transaction value of 31.94 million yuan [1]. Trading Information Summary - On May 23, the capital flow for Hualan Co., Ltd. showed a net outflow of 4.285 million yuan from main funds, while retail funds had a net inflow of 1.9505 million yuan and speculative funds saw a net inflow of 2.3345 million yuan [2][4]. Company Announcement Summary - Hualan Co., Ltd. signed a shareholder agreement with Ms. Dan Yexing to establish a joint venture with a registered capital of 7 million yuan. Hualan Co., Ltd. will contribute 4.298 million yuan, holding 61.4% of the joint venture, while Ms. Dan will contribute 2.702 million yuan, holding 38.6% [2][4]. - The joint venture will focus on the research, production, and sales of products such as Tibetan medicinal baths and plasters. This investment does not require approval from the board of directors or shareholders and does not constitute a related party transaction or major asset restructuring [2][4]. - The joint venture will be included in Hualan Co., Ltd.'s consolidated financial statements. The board will consist of three members, with Hualan Co., Ltd. appointing two directors and Ms. Dan appointing one. The chairman will be recommended and elected by Hualan Co., Ltd. [2][4].
晚间公告丨5月23日这些公告有看头
第一财经· 2025-05-23 15:00
Group 1 - Ningde Times participated in the completion of the Zeyuan Fund, with a total scale of 10.128 billion yuan, increasing by 50.42% from the previous announcement [3] - Zhongjin Gold's controlling shareholder plans to inject four companies into the company to resolve competition issues, including acquiring stakes in Inner Mongolia Jintao and others [4][5] - Keli Yuan plans to invest an additional 500 million yuan in a storage industry fund, increasing its total investment to 700 million yuan [6] Group 2 - China Shenhua intends to acquire 7.43% of the National Energy Group Financial Company for 2.929 billion yuan, which is expected to increase its net profit by 97 million yuan [7] - Weir Shares plans to issue H-shares and list on the Hong Kong Stock Exchange [8] - Hualan Shares is establishing a joint venture for Tibetan medicinal baths and plaster products, with a registered capital of 7 million yuan [15] Group 3 - Yunnan Copper plans to acquire 40% of Liangshan Mining through a share issuance, with the stock resuming trading on May 26 [10] - Ruishun Technology's subsidiary plans to establish a joint venture in Malaysia to provide automation solutions [11] - ST Quanwei's stock will be subject to additional risk warnings due to ongoing litigation involving a subsidiary [12] Group 4 - Hengfeng Information's controlling shareholder has terminated the agreement to transfer part of the company's shares, with no impact on control [13] - Huadian Technology's subsidiary has not yet commenced substantial construction on a polyurethane new materials project [14] - ST Yinjian will remove the delisting risk warning and some other risk warnings, changing its stock name [38] Group 5 - China Tonghao won approximately 3.789 billion yuan in contracts in the rail transit market from March to April [39] - Intercontinental Oil and Gas plans to invest about 848 million USD in the Iraq South Basra project [40][41] - Jiaying Pharmaceutical's subsidiary signed a contract for the development of a traditional Chinese medicine innovation project [42] Group 6 - Ruidong Intelligent signed a strategic cooperation agreement with Shunde Vocational and Technical College to enhance collaboration in technology [43] - Jiaojian Co. won a bid for a drainage project worth 225 million yuan [44] - Hengshun Vinegar's controlling shareholder plans to increase its stake in the company by 50 to 100 million yuan [45]
华兰股份(301093) - 关于对外投资设立合资公司的公告
2025-05-23 10:31
证券代码:301093 证券简称:华兰股份 公告编号:2025-046 江苏华兰药用新材料股份有限公司 关于对外投资设立合资公司的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 一、 对外投资概述 江苏华兰药用新材料股份有限公司(以下简称"华兰股份"或"华兰")近 日与单烨星女士签署了《股东协议》(以下简称"本协议"或"本股东协议")。 华兰股份将与单烨星女士设立一家合资公司(以下简称"合资公司"或"公 司"),合资公司的主要经营范围为:从事西藏药浴、膏药等产品的研发、生产 及销售业务(具体以公司成立后取得的营业执照记载为准)。合资公司的注册资 本为人民币 700 万元,华兰股份将以自有资金出资 429.8 万元人民币,占合资公 司注册资本的 61.4%。 根据《深圳证券交易所创业板股票上市规则》等相关法律法规规定,本次 投资事项在总经理审批权限范围内,无需提交董事会或股东大会审议批准。 本次对外投资不构成关联交易,亦不构成《上市公司重大资产重组管理办 法》规定的重大资产重组。 二、 共同投资方基本情况 | 姓名 | 单烨星 | | --- | --- ...
华兰股份:拟与单烨星共同出资700万元设立合资公司
news flash· 2025-05-23 10:21
Group 1 - The company, Hualan Co., Ltd. (301093), has signed a shareholder agreement with Ms. Dan Yexing to jointly establish a new joint venture with a registered capital of 7 million yuan [1] - Hualan Co., Ltd. will contribute 4.298 million yuan, accounting for 61.4% of the registered capital [1] - The main business scope of the joint venture will include research, production, and sales of products such as Tibetan medicinal baths and plasters [1]
华兰股份(301093) - 关于使用部分闲置募集资金和自有资金进行现金管理到期赎回并继续进行现金管理的公告
2025-05-22 09:16
证券代码:301093 证券简称:华兰股份 公告编号:2025-045 江苏华兰药用新材料股份有限公司 关于使用部分闲置募集资金和自有资金进行现金管理到期赎回 并继续进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司(以下简称"公司")分别于 2024 年 11 月 29 日、2024 年 12 月 18 日召开第五届董事会第三十次会议及第五届监事会第 二十七次会议、2024 年第七次临时股东大会,审议通过了《关于使用部分闲置募 集资金和自有资金进行现金管理的议案》,同意公司及子公司使用不超过人民币 130,000 万元的闲置募集资金(含超募资金,下同)和自有资金进行现金管理, 其中募集资金不超过 95,000 万元、自有资金不超过 35,000 万元。现金管理有效 期为公司股东大会审议通过之日起 12 个月内,上述额度在有效期内可循环滚动 使用。具体内容详见公司于 2024 年 11 月 30 日在指定信息披露媒体和巨潮资讯 网(www.cninfo.com.cn)上披露的《关于使用部分闲置募集资金和自有资金进 ...
华兰股份(301093) - 关于控股子公司完成工商变更登记并换发营业执照的公告
2025-05-21 07:42
证券代码:301093 证券简称:华兰股份 公告编号:2025-044 江苏华兰药用新材料股份有限公司 基于经营发展需要,江苏华兰药用新材料股份有限公司(以下简称"公司")的 控股子公司江苏华兰当盛生物科技有限公司(以下简称"华兰当盛")对其经营范围、 住所进行了变更。近日,华兰当盛已完成工商变更登记手续,并取得由江阴市数据局 下发的《登记通知书》以及《营业执照》。具体情况如下: 一、本次华兰当盛的经营范围、住所变更情况 | 变更事项 | 变更前 | 变更后 许可项目:特定印刷品印刷;包装装潢印 | | --- | --- | --- | | | | 刷品印刷(依法须经批准的项目,经相关 | | | 一般项目:工程和技术研究和试验发展; | 部门批准后方可开展经营活动,具体经 | | | 技术服务、技术开发、技术咨询、技术交 | 营项目以审批结果为准) | | | 流、技术转让、技术推广;新材料技术推 | 一般项目:工程和技术研究和试验发展; | | | 广服务;医用包装材料制造;包装材料 | 技术服务、技术开发、技术咨询、技术交 | | 经营范围 | 及制品销售;卫生用品和一次性使用医 | 流、技术转让、技 ...
华兰股份(301093) - 北京植德律师事务所关于江苏华兰药用新材料股份有限公司2024年年度股东大会的法律意见书
2025-05-16 11:54
北京植德律师事务所 关于江苏华兰药用新材料股份有限公司 2024 年年度股东大会的 法律意见书 植德京(会)字[2025]0058 号 二〇二五年五月 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编:100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel):010-56500900 传真(Fax):010-56500999 www.meritsandtree.com 北京植德律师事务所 关于江苏华兰药用新材料股份有限公司 北京植德律师事务所(以下简称"本所")接受江苏华兰药用新材料股份有 限公司(以下简称"公司"或"华兰股份")的委托,指派律师出席并见证公司 2024年年度股东大会(以下简称"本次会议")。 本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》 (以下简称"《股东会规则》")、《律师事 ...
华兰股份(301093) - 2024年年度股东大会决议公告
2025-05-16 11:54
证券代码:301093 证券简称:华兰股份 公告编号:2025-043 江苏华兰药用新材料股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 特别提示: 1、 本次股东大会未出现否决议案的情形。 一、 会议召开和出席情况 (一) 会议召开时间 通过深圳证券交易所交易系统进行网络投票的时间为:2025 年 5 月 16 日 (星期五)9:15-9:25,9:30-11:30 和 13:00-15:00; 通过深圳证券交易所互联网投票系统投票的具体时间为:2025 年 5 月 16 日 (星期五)9:15-15:00。 (六) 本次股东大会的召集、召开、表决符合《中华人民共和国公司法》 《深圳证券交易所创业板股票上市规则》等有关法律、行政法规、部门规章、 规范性文件及《公司章程》的规定。 (七) 会议出席情况 1、 股东出席情况 通过现场和网络投票的股东 83 人,代表股份 47,169,431 股,占公司有表决 权股份总数的 37.3445%。其中:通过现场投票的股东 5 人,代表股份 40,275,246 股,占公司 ...
2025年中国医药包装行业市场现状分析及发展趋势预测报告(智研咨询发布)
Sou Hu Cai Jing· 2025-05-15 09:51
Core Insights - The pharmaceutical packaging industry in China is experiencing steady growth, with the market size projected to reach 143.96 billion yuan in 2024, driven by the expansion of the domestic pharmaceutical market and the rapid development of the pharmaceutical industry [2] - Long-term growth prospects for the pharmaceutical packaging market are supported by factors such as an aging population, increased health awareness, and improvements in the healthcare system, leading to a rising demand for pharmaceuticals and consequently for packaging [2] Industry Definition and Classification - Pharmaceutical packaging refers to a range of materials and containers used to protect drugs, facilitate storage and transportation, promote sales, provide drug information, and ensure medication safety [2] - It conveys important information regarding the quality, safety, and efficacy of the drugs through its design, materials, and structure [2] Industry Chain Analysis - The pharmaceutical packaging industry chain includes multiple sectors: raw material supply, packaging material manufacturing, drug packaging and application, and auxiliary processes [4] - The upstream sector involves the supply of raw materials such as plastics, glass, metals, and paper, which are crucial for the stability and quality of packaging materials [4] - The midstream sector processes these raw materials into various packaging forms, ensuring properties like sealing and moisture resistance [4] - The downstream sector includes pharmaceutical manufacturers and distributors who utilize these packaging materials for drug sales [4] - The industry is evolving towards environmentally friendly, intelligent, and personalized packaging solutions due to rising environmental awareness and technological advancements [4] Development History - The development of the pharmaceutical packaging industry in China has gone through three stages: initial development, rapid expansion, and transformation and innovation [6] - The initial stage was characterized by reliance on imports and limited technology, while the rapid expansion phase saw increased competition and the introduction of advanced management practices [6] - Currently, the industry is focused on transformation, with increased R&D investment and a shift towards eco-friendly and smart packaging solutions, marking a transition from technology catch-up to innovation leadership [6] Related Reports - The report by Zhiyan Consulting analyzes the competitive landscape and investment potential of the pharmaceutical packaging industry, aiming to identify future market trends and development potential [8] - It provides a comprehensive analysis of the industry’s operational status, import and export dynamics, and competitive structure, projecting trends for 2025 [10]
华兰股份(301093) - 关于公司控股股东、实际控制人自愿承诺不减持公司股份的公告
2025-05-13 10:22
关于公司控股股东、实际控制人自愿承诺不减持公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司(以下简称"公司")于近日收到了公司控股 股东江阴华兰机电科技有限公司、实际控制人(华一敏先生、华国平先生、杨菊兰女 士)出具的《关于自愿承诺不减持的承诺函》,现将具体内容公布如下: 一、本次承诺的主要内容 基于对公司未来发展前景的信心以及内在价值的认可,为支持公司持续、稳定、 健康发展,同时为增强广大投资者信心,切实维护投资者权益和资本市场的稳定,本 人/本公司自愿承诺:自本承诺公告之日起 12 个月内,不以任何形式减持本股东直接 和间接持有的公司股票;承诺期内如发生资本公积转增股本、派送股票红利、配股、 增发等产生的股份,亦遵守上述承诺。若违反上述承诺,减持股份所得的收益全部归 公司所有,并依法承担由此产生的法律责任。 证券代码:301093 证券简称:华兰股份 公告编号:2025-042 江苏华兰药用新材料股份有限公司 三、其他说明 公司董事会将监督上述相关人员严格遵守承诺。若上述相关人员未遵守相关承 诺,公司董事会将保 ...